Perdagangan Vir Biotechnology VIR

VirBiotechnology diagram langsung

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tampilkan lebih banyak
Frances Wang 2025 Mei 13, 16:00

XRP News Today: XRP Rises on Increased Bank Demand in the US

Cryptocurrencies
Tommy Yap 2025 Mei 13, 16:00

Morning Note: Tencent's Report in Focus; Gold Affected by Trade Optimism; Oil Stable

Morning Note China Commodities
Frances Wang 2025 Mei 12, 16:00

ADA crypto price forecast: What factors influence the price of Cardano?

Cryptocurrencies
Tommy Yap 2025 Mei 12, 16:00

Morning Note: Tariff Rollback Sparks Stock Rally; US CPI Watch; Bailey's Speech

Morning Note Equities
Tommy Yap 2025 Mei 12, 04:00

Morning Note: US Surplus Expected; Denmark Inflation; UK Retail Sales Forecast

Morning Note EUR
Frances Wang 2025 Mei 11, 16:00

How the US-China Trade War Influenced Global Commodity Markets?

Commodities
Tommy Yap 2025 Mei 09, 21:00

Week Ahead: U.S. Inflation Data in Spotlight

Forex Indices
Frances Wang 2025 Mei 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds

Info

Spread

0.03

Spread (%)

0.6787 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar buka

Rabu

13:31 - 19:59

Senin

13:31-19:59

Selasa

13:31-19:59

Kamis

13:31-19:59

Jumat

13:31-19:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

731739200

Saham yang Beredar

138064000

Tanggal Penghasilan (Berikutnya)

0000-00-00

Hasil Div

Tanggal Non-Dividen

Proyeksi tingkat dividen tahunan

0

Proyeksi hasil dividen tahunan

0

EPS

-4.23

Pelajari lebih lanjut tentang instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tampilkan lebih banyak
Trustpilot